Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BNGO
stocks logo

BNGO

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
6.90M
-11.23%
--
--
7.83M
+28.98%
--
--
8.85M
+8.42%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by -0.54% over the past three months. During the same period, the stock price has changed by 5.19%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.54%
In Past 3 Month
Stock Price
Go Up
up Image
+5.19%
In Past 3 Month
4 Analyst Rating
up Image0
Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 7.33 USD with a low forecast of 4.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
up Image0
Current: 3.650
sliders
Low
4.00
Averages
7.33
High
10.00
up Image0
Current: 3.650
sliders
Low
4.00
Averages
7.33
High
10.00
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$8
2025-05-20
Reason
Maxim Group
Jason McCarthy
Price Target
$8
2025-05-20
Upgrades
Hold
to
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Initiates
$10
2025-04-09
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$10
2025-04-09
Initiates
Strong Buy
Reason
Scotiabank
Sung Ji Nam
Hold
Maintains
$1 → $4
2025-04-02
Reason
Scotiabank
Sung Ji Nam
Price Target
$1 → $4
2025-04-02
Maintains
Hold
Reason
Scotiabank raised the firm's price target on Bionano Genomics to $4 from $1 and keeps a Sector Perform rating on the shares. Despite the challenging macroeconomic environment in 2024, there were "bright spots" for the company, such as double-digit growth for Consumables and Software revenues, the analyst tells investors. The firm is favoring the sidelines until it has better visibility into the company's near- to medium-term growth potential.
Ladenburg Thalmann
Jeff Cohen
Strong Buy
to
Hold
Downgrades
n/a
2024-11-15
Reason
Ladenburg Thalmann
Jeff Cohen
Price Target
n/a
2024-11-15
Downgrades
Strong Buy
to
Hold
Reason
Ladenburg analyst Jeffrey Cohen downgraded Bionano Genomics to Neutral from Buy.
BTIG
Mark Massaro
Strong Buy
to
Hold
Downgrades
n/a
2024-09-10
Reason
BTIG
Mark Massaro
Price Target
n/a
2024-09-10
Downgrades
Strong Buy
to
Hold
Reason
Scotiabank
Sung Ji Nam
Buy
to
Hold
Downgrades
$6 → $1
2024-08-28
Reason
Scotiabank
Sung Ji Nam
Price Target
$6 → $1
2024-08-28
Downgrades
Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bionano Genomics Inc (BNGO.O) is -0.49, compared to its 5-year average forward P/E of -6.98. For a more detailed relative valuation and DCF analysis to assess Bionano Genomics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.98
Current PE
-0.49
Overvalued PE
3.25
Undervalued PE
-17.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.39
Current EV/EBITDA
-0.85
Overvalued EV/EBITDA
5.29
Undervalued EV/EBITDA
-18.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.59
Current PS
0.40
Overvalued PS
61.81
Undervalued PS
-14.63

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BNGO News & Events

Events Timeline

(ET)
2025-05-19
08:13:36
Bionano Genomics announces second Category I CPT code for OGM
select
2025-05-14 (ET)
2025-05-14
16:13:52
Bionano Genomics sees FY25 revenue $26M-$30M, consensus $30.33M
select
2025-05-14
16:12:15
Bionano Genomics reports Q1 revenue $6.46M, consensus $6.25M
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
05-19Newsfilter
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

  • New CPT Code Announcement: Bionano Laboratories has received a new Category I CPT code from the American Medical Association for optical genome mapping (OGM) to detect genetic disorders, which will aid in reimbursement for their OGM-Dx tests starting January 1, 2026.

  • Impact on Clinical Testing: This new code, following a previous one issued in 2024, signifies the growing acceptance and utility of OGM in clinical genetic testing, potentially enhancing its application beyond oncology to other areas of genetic disorders.

Preview
2.0
05-15SeekingAlpha
Biggest stock movers Thursday: CSCO, BNGO, and more

  • Stock Market Overview: Stock futures fell as investors reacted to US-China trade tensions and awaited inflation data, while notable stock movements included Cisco's 4% rise after strong earnings and guidance, and Bionano Genomics' 20% increase despite a revenue decline.

  • Major Stock Declines: Luminar Technologies saw a 10% drop due to mixed results and leadership changes, while New Fortress Energy plummeted 31% after missing Q1 expectations significantly, although it anticipates future earnings improvement from new projects.

Preview
7.0
05-15SeekingAlpha
Bionano outlines $26M–$30M 2025 revenue target as strategic pivot drives higher gross margin

  • Management Strategy: Bionano Genomics is shifting its focus from customer acquisition to supporting routine users of its Optical Genome Mapping products, resulting in a 26% revenue decline in Q1 2025 but improved gross margins and reduced operating expenses.

  • Financial Outlook: The company updated its full-year revenue guidance to $26 million to $30 million, citing global trade uncertainties, while maintaining confidence in the stability of gross margins and growth among engaged customers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bionano Genomics Inc (BNGO) stock price today?

The current price of BNGO is 3.65 USD — it has decreased -1.35 % in the last trading day.

arrow icon

What is Bionano Genomics Inc (BNGO)'s business?

Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sells the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

arrow icon

What is the price predicton of BNGO Stock?

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 7.33 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bionano Genomics Inc (BNGO)'s revenue for the last quarter?

Bionano Genomics Inc revenue for the last quarter amounts to 6.46M USD, decreased -26.37 % YoY.

arrow icon

What is Bionano Genomics Inc (BNGO)'s earnings per share (EPS) for the last quarter?

Bionano Genomics Inc. EPS for the last quarter amounts to -1.15 USD, decreased -96.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bionano Genomics Inc (BNGO)'s fundamentals?

The market is revising Downward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by -0.54% over the past three months. During the same period, the stock price has changed by 5.19%.
arrow icon

How many employees does Bionano Genomics Inc (BNGO). have?

Bionano Genomics Inc (BNGO) has 344 emplpoyees as of June 14 2025.

arrow icon

What is Bionano Genomics Inc (BNGO) market cap?

Today BNGO has the market capitalization of 12.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free